Faculty Collaboration Database

Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. Semin Cardiothorac Vasc Anesth 2021 Sep;25(3):200-207

Date

01/05/2021

Pubmed ID

33393437

DOI

10.1177/1089253220982183

Scopus ID

2-s2.0-85098732706 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

There are limited data to guide the use of anticoagulation in cirrhotic patients prior to liver transplantation especially when using direct oral anticoagulants. In this article, we present 2 cases. The first is a 42-year-old male with cirrhosis complicated by portal vein thrombosis (PVT) treated with dabigatran who underwent orthotopic liver transplantation without complication. The second case is a 65-year-old man with alcoholic cirrhosis complicated by PVT treated with dabigatran who underwent orthotopic liver transplantation and required reoperation for surgical bleeding. Both patients were treated with dabigatran's reversal agent idarucizumab prior to incision. In this case series, we discuss the treatment of cirrhotic patients with various anticoagulants, considerations for anticoagulant selection and reversal prior to liver transplant, and questions for future investigation.

Author List

Williams C, Stewart E, Conzen KD, Wolf S, Tran TT

Author

Timothy Tran MD Associate Professor in the Anesthesiology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Antibodies, Monoclonal, Humanized
Anticoagulants
Dabigatran
Humans
Liver Transplantation
Male
Portal Vein
Venous Thrombosis